EXCLUSIVE: U.S. FDA Posts Import Alert For Ranbaxy’s Mohali Site; Adds Mohali To Consent Decree
This article was originally published in PharmAsia News
Ranbaxy’s newest manufacturing site at Mohali, India, is prohibited by FDA from shipping products to the United States in a move that could impact the company’s chances for approval of valsartan.
You may also be interested in...
Ranbaxy’s $500 Million GMP Settlement Would Be Second Most Expensive For Rx Manufacturing Violations
Ranbaxy Laboratories said it has signed a consent decree with FDA and set aside $500 million to settle a related Department of Justice investigation involving GMP violations and data integrity issues at its Indian facilities.
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.